Literature DB >> 20671216

A maladaptive role for EP4 receptors in podocytes.

Erin M Stitt-Cavanagh1, Wissam H Faour, Kaede Takami, Anthony Carter, Barbara Vanderhyden, Youfei Guan, Andre Schneider, Matthew D Breyer, Christopher R J Kennedy.   

Abstract

Inhibition of p38 mitogen-activated protein kinase and cyclooxygenase-2 reduces albuminuria in models of chronic kidney disease marked by podocyte injury. Previously, we identified a feedback loop in podocytes whereby an in vitro surrogate for glomerular capillary pressure (i.e., mechanical stretch) along with prostaglandin E(2) stimulation of its EP4 receptor induced cyclooxygenase-2 in a p38-dependent manner. Here we asked whether stimulation of EP4 receptors would exacerbate glomerulopathies associated with enhanced glomerular capillary pressure. We generated mice with either podocyte-specific overexpression or depletion of the EP4 receptor (EP4(pod+) and EP4(pod-/-), respectively). Glomerular prostaglandin E(2)-stimulated cAMP levels were eightfold greater for EP4(pod+) mice compared with nontransgenic (non-TG) mice. In contrast, EP4 mRNA levels were >50% lower, and prostaglandin E(2)-induced cAMP synthesis was absent in podocytes isolated from EP4(pod-/-) mice. Non-TG and EP4(pod+) mice underwent 5/6 nephrectomy and exhibited similar increases in systolic BP (+25 mmHg) by 4 weeks compared with sham-operated controls. Two weeks after nephrectomy, the albumin-creatinine ratio of EP4(pod+) mice (3438 μg/mg) was significantly higher than that of non-TG mice (773 μg/mg; P < 0.0001). Consistent with more severe renal injury, the survival rate for nephrectomized EP4(pod+) mice was significantly lower than that for non-TG mice (14 versus 67%). In contrast, 6 weeks after nephrectomy, the albumin-creatinine ratio of EP4(pod-/-) mice (753 μg/mg) was significantly lower than that of non-TG mice (2516 μg/mg; P < 0.05). These findings suggest that prostaglandin E(2), acting via EP4 receptors contributes to podocyte injury and compromises the glomerular filtration barrier.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20671216      PMCID: PMC3013547          DOI: 10.1681/ASN.2009121234

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  45 in total

1.  Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor.

Authors:  Lamine Aoudjit; Anna Potapov; Tomoko Takano
Journal:  Am J Physiol Renal Physiol       Date:  2006-01-05

Review 2.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis.

Authors:  S J Shankland
Journal:  Kidney Int       Date:  2006-05-10       Impact factor: 10.612

3.  Overexpression of cyclooxygenase-2 predisposes to podocyte injury.

Authors:  Huifang Cheng; Suwan Wang; Young-Il Jo; Chuan-Ming Hao; Mingzhi Zhang; Xiaofeng Fan; Chris Kennedy; Matthew D Breyer; Gilbert W Moeckel; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2007-01-03       Impact factor: 10.121

4.  Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure.

Authors:  S Vukicevic; P Simic; F Borovecki; L Grgurevic; D Rogic; I Orlic; W A Grasser; D D Thompson; V M Paralkar
Journal:  Kidney Int       Date:  2006-07-26       Impact factor: 10.612

5.  Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes.

Authors:  Zhuowei Wang; Tao Jiang; Jinping Li; Gregory Proctor; James L McManaman; Scott Lucia; Streamson Chua; Moshe Levi
Journal:  Diabetes       Date:  2005-08       Impact factor: 9.461

6.  Activation of Galpha q-coupled signaling pathways in glomerular podocytes promotes renal injury.

Authors:  Liming Wang; Timothy A Fields; Kathy Pazmino; Qunsheng Dai; James L Burchette; David N Howell; Thomas M Coffman; Robert F Spurney
Journal:  J Am Soc Nephrol       Date:  2005-11-02       Impact factor: 10.121

Review 7.  From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy.

Authors:  Gunter Wolf; Sheldon Chen; Fuad N Ziyadeh
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

8.  Rho GTPase and cAMP/protein kinase A signaling mediates myocilin-induced alterations in cultured human trabecular meshwork cells.

Authors:  Xiang Shen; Takahisa Koga; Bum-Chan Park; Nirmala SundarRaj; Beatrice Y J T Yue
Journal:  J Biol Chem       Date:  2007-11-05       Impact factor: 5.157

9.  Puromycin induces reversible proteinuric injury in transgenic mice expressing cyclooxygenase-2 in podocytes.

Authors:  Young-Il Jo; Huifang Cheng; Suwan Wang; Gilbert W Moeckel; Raymond C Harris
Journal:  Nephron Exp Nephrol       Date:  2007-09-21

10.  Podocyte loss in aging OVE26 diabetic mice.

Authors:  Jennifer M Teiken; Janice L Audettey; Donna I Laturnus; Shirong Zheng; Paul N Epstein; Edward C Carlson
Journal:  Anat Rec (Hoboken)       Date:  2008-01       Impact factor: 2.064

View more
  30 in total

1.  Transforming growth factor-β1 and phosphatases modulate COX-2 protein expression and TAU phosphorylation in cultured immortalized podocytes.

Authors:  Maya S Abdallah; Christopher R J Kennedy; Joseph S Stephan; Pamela Abou Khalil; Mohammad Mroueh; Assaad A Eid; Wissam H Faour
Journal:  Inflamm Res       Date:  2017-10-30       Impact factor: 4.575

Review 2.  Drug discovery in focal and segmental glomerulosclerosis.

Authors:  Nick Pullen; Alessia Fornoni
Journal:  Kidney Int       Date:  2016-04-23       Impact factor: 10.612

3.  Janus Kinase 2 Regulates Transcription Factor EB Expression and Autophagy Completion in Glomerular Podocytes.

Authors:  Tamadher A Alghamdi; Syamantak Majumder; Karina Thieme; Sri N Batchu; Kathryn E White; Youan Liu; Angela S Brijmohan; Bridgit B Bowskill; Suzanne L Advani; Minna Woo; Andrew Advani
Journal:  J Am Soc Nephrol       Date:  2017-04-19       Impact factor: 10.121

4.  Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats.

Authors:  Kazuhiko Mizukami; Hiroyuki Yoshida; Eisuke Nozawa; Koichi Wada; Tohru Ugawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-15       Impact factor: 3.000

5.  Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease.

Authors:  Syamantak Majumder; Karina Thieme; Sri N Batchu; Tamadher A Alghamdi; Bridgit B Bowskill; M Golam Kabir; Youan Liu; Suzanne L Advani; Kathryn E White; Laurette Geldenhuys; Karthik K Tennankore; Penelope Poyah; Ferhan S Siddiqi; Andrew Advani
Journal:  J Clin Invest       Date:  2017-12-11       Impact factor: 14.808

6.  Urinary podocyte microparticles identify prealbuminuric diabetic glomerular injury.

Authors:  Dylan Burger; Jean-Francois Thibodeau; Chet E Holterman; Kevin D Burns; Rhian M Touyz; Christopher R J Kennedy
Journal:  J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 10.121

7.  eNOS deficiency predisposes podocytes to injury in diabetes.

Authors:  Darren A Yuen; Bailey E Stead; Yanling Zhang; Kathryn E White; M Golam Kabir; Kerri Thai; Suzanne L Advani; Kim A Connelly; Tomoko Takano; Lei Zhu; Alison J Cox; Darren J Kelly; Ian W Gibson; Takamune Takahashi; Raymond C Harris; Andrew Advani
Journal:  J Am Soc Nephrol       Date:  2012-09-20       Impact factor: 10.121

Review 8.  Hyperfiltration-associated biomechanical forces in glomerular injury and response: Potential role for eicosanoids.

Authors:  Mukut Sharma; Ram Sharma; Ellen T McCarthy; Virginia J Savin; Tarak Srivastava
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-01-17       Impact factor: 3.072

Review 9.  The complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney function.

Authors:  Torrance Green; Alexis A Gonzalez; Kenneth D Mitchell; L Gabriel Navar
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

10.  Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist.

Authors:  Kazuhiko Mizukami; Hiroaki Kamada; Hiroyuki Yoshida; Ikuko Ishii; Eisuke Nozawa; Koichi Wada; Tohru Ugawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.